Quell Therapeutics, a UK biotech start-up, has secured a $85mn upfront payment and up to $2bn in potential milestone payments from pharmaceutical major AstraZeneca for a research collaboration and licensing agreement. The partnership aims to develop treatments for autoimmune diseases, specifically type 1 diabetes and inflammatory bowel disease, by genetically engineering regulatory T-cells to reduce immune response. The cell therapy start-up is planning clinical trials for a new therapy designed to prevent liver transplant rejections. Before the AstraZeneca deal, Quell raised $220mn from investors, with a stake owned by Syncona. McGill, Quell CEO, believes the therapy could be simpler and cheaper, even for off-the-shelf cells from other donors.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
